The corona pandemic has ensured that the term "mRNA" is now also known to a large public beyond laboratories and lecture halls. However, the molecule is much more than an important component of a ...

The clinical potential of mRNA was revealed with COVID-19 vaccines, but that was just the beginning. “Today, this Nobel prize–winning technology is being leveraged for many therapeutic applications, ...

LineaRx will present its Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) - as a ...

Takara Bio Europe (TBE) announced the launch of new High Quality (HQ) grade mRNA production enzymes "T7 RNA polymerase, HQ" and "Pyrophosphatase (inorganic), HQ" suitable for pre-clinical and process ...

The development of nucleic-acid therapeutics, ranging from aptamers and antisense RNA to messenger RNA (mRNA)-based vaccines and gene therapies, is a rapidly evolving industry that has the potential ...

Stay ahead in the booming mRNA market, projected to reach $63.28 billion by 2025, with the 3 rd mRNA Process Development & Manufacturing Summit 2025 - Europe’s premier industry-focused forum dedicated ...

mRNA‑based products are rapidly growing in the biotherapeutics space. Important considerations need to be made to develop a process for mRNA synthesis that consistently generates high‑yield and ...

A platform approach to bioprocessing uses the same set of protocols and systems found during early phase development. Scientists then transfer the protocols, by either scaling-up or scaling-out, ...

With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is hindered by its production ...

The 3rd mRNA Process Development and Manufacturing Summit returns to Boston this September, poised to help you implement high throughput process development, scale-up mRNA synthesis and purification, ...